Canaccord analyst Sumant Kulkarni raised the firm’s price target on Biogen to $330 from $325 and keeps a Buy rating on the shares. The analyst said we believe our thesis is very much on track, and the stock is poised for upside as we head into the important action dates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen price target raised to $325 from $310 at Oppenheimer
- Biogen price target lowered to $302 from $307 at Barclays
- FDA approves Ionis Pharma/Biogen’s QALSODY as first treatment in ALS
- Biogen price target raised to $371 from $349 at Morgan Stanley
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS